2020 AACC Annual Scientific Meeting Press Program

GenScript Granted Authorization for cPass™ SARS-CoV-2 Neutralization Antibody Detection Test in Brazil

World's first test capable of detecting virus-blocking antibodies that can be performed in standard labs in under an hour

Newswise — PISCATAWAY, NEW JERSEY, December 14, 2020 – GenScript USA Inc., the world’s leading research reagent provider, announced today that Brazil's National Health Surveillance Agency (ANVISA) (Agência Nacional de Vigilância Sanitária) has authorized the use of the cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit for detecting neutralizing antibodies. The cPass test is the first and only ANVISA authorized test for detecting neutralizing antibodies to SARS-CoV-2. Neutralizing antibodies specifically block the ability of a virus to infect a cell and are well-recognized to confer immunity.

"We're extremely pleased to receive emergency use authorization in Brazil, and look forward to rapidly distributing it to labs, healthcare institutions and pharmaceutical firms across the country," said David Martz, vice president of new product management in Life Science Group at GenScript, “Because the cPass kit detects the specific antibodies that block the virus, it's a particularly valuable tool for monitoring patients for virus-blocking antibodies after they have recovered from COVID-19, as well as for determining the duration of vaccine protection post immunization."

The cPass kit is also the first and only ANVISA and EUA authorized test to specifically detect neutralizing (virus blocking) antibodies in patient samples without the use of live virus. The conventional method to measure neutralizing antibodies in the patient samples requires the use of live cells and obtaining results takes multiple days in very controlled, high safety environment (BSL3). In contrast, the cPass kit is an ELISA assay and can be performed in most standard laboratories with short turnaround time (~1hr).

Authorization for use of cPass in Brazil follows emergency use authorization of the test by the U.S. Food and Drug Administration in November, and provisional use in Singapore earlier this year. The kit has also been granted a CE Mark in Europe. And is the only neutralizing antibody test to have obtained all of these authorizations by regulatory authorities.

The cPass™ kit is another example of GenScript’s continued commitment to supporting the healthcare community in combatting COVID-19 infections.

The cPass kit is being distributed in Brazil by NL Diagnostica.

 

 

About GenScript Biotech Corporation

GenScript Biotech Corporation (Stock Code: 1548.HK) is a global biotechnology group. Based on its leading gene synthesis technology, GenScript has developed four major platforms including the global cell therapy platform, the biologics contract development and manufacturing organization (CDMO) platform, the contract research organization (CRO) platform and the industrial synthesis product platform.

GenScript was founded in New Jersey, US in 2002 and listed on the Hong Kong Stock Exchange in 2015. GenScript's business operation spans over 100 countries and regions worldwide, with legal entities located in the U.S., Mainland China, Hong Kong, Japan, Singapore, Netherlands and Ireland. GenScript has provided premium, convenient, and reliable products and services for over 100,000 customers.

GenScript has a number of intellectual property rights and technical secrets, including more than 100 patents and over 270 patent applications. As of December 31, 2019, GenScript's products and services have been cited by 42,200 peer-reviewed journal articles worldwide.

For more information visit www.genscript.com.

 



Filters close

Showing results

110 of 5820
access_time Embargo lifts in 2 days
Embargo will expire: 15-Jun-2021 11:00 AM EDT Released to reporters: 14-Jun-2021 5:20 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 15-Jun-2021 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: For Transplant Recipients, Third Time May Be the Charm for Better COVID Vaccine Protection
Released: 14-Jun-2021 5:15 PM EDT
For Transplant Recipients, Third Time May Be the Charm for Better COVID Vaccine Protection
Johns Hopkins Medicine

In a study published today in the Annals of Internal Medicine, Johns Hopkins Medicine researchers say they believe that, for the first time, there is evidence to show that three doses of vaccine increase antibody levels against SARS-CoV-2 — the virus that causes COVID 19 — more than the standard two-dose regimen for people who have received solid organ transplants.

Newswise: Broadway1_DTLA_sz.lowres-768x512.jpg
Released: 14-Jun-2021 4:05 PM EDT
What’s Next: The Ongoing Urban Exodus
University of California, Irvine

Many employees have come to prefer working from home after being forced to do so more than a year ago when the pandemic started. By some estimates, at least one-quarter of employees will still be working remotely multiple days a week at the end of 2021. For those whose jobs allow it, being untethered from the office might mean moving farther away from it – by a few miles or a few hundred.

Newswise: 267701_web.jpg
Released: 14-Jun-2021 2:50 PM EDT
New model accounts for the effect of behavior changes to predict COVID-19 cases
Brown University

By adding behavioral components to an infectious disease model, Brown University researchers have developed a new modeling approach that captures the peaks and valleys in new COVID-19 cases seen over the past 16 months.

Newswise: Masking, breakthrough infections and telehealth: Keck Medicine of USC experts on life after June 15
Released: 14-Jun-2021 2:05 PM EDT
Masking, breakthrough infections and telehealth: Keck Medicine of USC experts on life after June 15
Keck Medicine of USC

June 15 is a banner day in California. Most COVID-19 statewide restrictions will be eliminated, including physical distancing and in many situations, mask mandates. How will life change and how will it stay the same? Keck Medicine of USC experts weigh in on what to expect next in the golden state.

access_time Embargo lifts in 2 days
Embargo will expire: 15-Jun-2021 8:00 AM EDT Released to reporters: 14-Jun-2021 11:40 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 15-Jun-2021 8:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: California Reopening: Experts Say Keep Masks Handy
Released: 14-Jun-2021 10:35 AM EDT
California Reopening: Experts Say Keep Masks Handy
Cedars-Sinai

This week brings a milestone to pandemic-weary Californians: As of June 15, California public health guidelines that have been in place during the 15 months of the COVID-19 pandemic will be relaxed. Those who are fully vaccinated against COVID-19 will be able to go mask-free in most situations, but Cedars-Sinai infectious disease experts suggest masks, an important tool in preventing transmission of the virus, will be with us a while longer.

Released: 14-Jun-2021 9:45 AM EDT
People with Health Insurance Vaccinated More Than Those Without, Survey Finds
Rutgers University-New Brunswick

People with health insurance are receiving the COVID-19 vaccine at a higher rate than those without insurance, despite the vaccine being free, according to a national survey from the Edward J. Bloustein School of Planning and Public Policy at Rutgers University-New Brunswick.

Newswise: Virtual Event For June 17, 11AM EDT: COVID-19 Vaccines and Male Fertility
Released: 14-Jun-2021 8:55 AM EDT
Virtual Event For June 17, 11AM EDT: COVID-19 Vaccines and Male Fertility
Newswise

This upcoming JAMA-published study examined whether the COVID-19 vaccine impacts male fertility.

Newswise:Video Embedded study-links-covid-19-public-health-efforts-to-dramatic-drop-in-copd-hospitalizations
VIDEO
Released: 14-Jun-2021 8:00 AM EDT
Study Links COVID-19 Public Health Efforts to Dramatic Drop in COPD Hospitalizations
University of Maryland Medical Center

Public health measures designed to reduce the spread of the COVID-19 virus may have fostered a substantial side benefit: A 53 percent drop in hospital admissions for chronic obstructive pulmonary disease (COPD), likely due to a drop in circulating seasonal respiratory viruses such as influenza.


Showing results

110 of 5820

close
1.39248